Cannabix Technologies Adds Dr. David Hasman to Initiate Marijuana Breathalyzer Trials in British Columbia

VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 25, 2017) - Cannabix Technologies Inc. (CSE:BLO)(CSE:BLO.CN)(OTC PINK:BLOZF) (the "Company or Cannabix") developer of the Cannabix Marijuana Breathalyzer for law enforcement and the workplace, is pleased to announce that Dr. David Hasman has joined its scientific team to initiate trials in Vancouver, British Columbia. Dr. David Hasman is with Forensic Science and Technology at the British Columbia Institute of Technology (BCIT) and has been providing his expertise in the LC/MS/MS method for fentanyl and analogues for the B.C. Provincial Toxicology Centre in Vancouver.

Dr. Hasman received his PhD in Chemical Physics from the University of California and was a postdoctoral fellow at the University of British Columbia. Joining a Vancouver based laboratory he was involved in method development for therapeutic drug monitoring and was part of an effort to develop a mass spectral drug library for Agriculture Canada.

After a career at Hewlett-Packard and Agilent Technologies Dr. Hasman taught chromatographic based analysis at BCIT and University of British Columbia. During that period, he joined BCIT Forensics Sciences and formed Procyon Research Inc. Procyon Research is involved in GC/MS and LC/MS/MS method development in forensics, natural products, and environmental disciplines.

Cannabix is developing its FAIMS- (field asymmetric waveform ion mobility spectrometry) based marijuana breathalyzer for the detection of delta-9-tetrahydrocannabinol ("THC") in human breath. The addition of Dr. Hasman to our Florida-Vancouver scientific team, will broaden our testing capabilities in Vancouver with human subjects using the Cannabix Marijuana Breathalyzer Beta prototype. The Company is substantially increasing its testing ability with new equipment and staff joining the Vancouver operation. Over the last several weeks, the Company has been developing a new "front end" breath intake system and calibrating decay signal intensities.

Dr. Raj Attariwala, commented, "We are excited to have Dr. Hasman join our Vancouver team as we prepare for trials using the patented FAIMS device with court accepted techniques of mass spectroscopy. His expertise in toxicology and forensic mass spec have been instrumental with government toxicology labs during the recent fentanyl crisis in BC and his skills will be invaluable as we prepare for trials with the Cannabix marijuana breathalyzer device."

About Cannabix Technologies Inc.

Cannabix Technologies Inc. is a leader in marijuana breathalyzer development for law enforcement and the workplace. Cannabix has established breath testing technologies in the pursuit of bringing durable, portable hand-held tools to market to enhance detection of marijuana impaired driving offences on roads at a time when marijuana is becoming legal in many global jurisdictions. Cannabix is working to develop drug-testing devices that will detect THC- the psychoactive component of marijuana that causes intoxication- using breath samples. In particular, Cannabix is focused on developing breath testing devices for detection of recent use of THC, in contrast to urine testing for THC metabolite that requires an invasive collection and reflects use days or even weeks earlier. The devices will also be useful for other practical applications such as testing employees in the workplace where intoxication by THC can be hazardous.

We seek Safe Harbor.

On behalf of the Board of Directors

Rav Mlait, CEO

Cannabix Technologies Inc.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking information that involves various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company, such as final development of a commercial or prototype product(s), successful trial or pilot of company technologies, no assurance that commercial sales of any kind actually materialize; no assurance the Company will have sufficient funds to complete product development. There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including: (i) adverse market conditions; (ii) risks regarding protection of proprietary technology; (iii) the ability of the Company to complete financings; (v) the ability of the Company to develop and market its future product; and (vi) risks regarding government regulation, managing and maintaining growth, the effect of adverse publicity, litigation, competition and other factors which may be identified from time to time in the Company's public announcements and filings. There is no assurance that the marijuana breathalyzer business will provide any benefit to the Company, and no assurance that any proposed new products will be built or proceed. There is no assurance that existing "patent pending" technologies licensed by the Company will receive patent status by regulatory authorities. The Company is not currently selling commercial breathalyzers. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company does not intend to update these forward-looking statements.